ARCHIVES

As Bristol’s Final Defenses Fall, IVAX Prepares Launch Of Generic Paclitaxel.

This article is from The Cancer Letter archive.

Vol. 26 No. 38 | October 20, 2000

Download PDF Visit The Full Archive

Related Articles

DeVita Distressed Over “Misinformation” Circulation On Organ Systems Program

April 8, 1983

FDA Approvals: Lymphoseek Label Updated to Include Head and Neck SCC

June 27, 2014

House Subcommittee allocates $11.3 Billion To NIH, $2.1 Bil. To NCI

June 17, 1994

FDA Codifies Rules For Expanded Access, Charging For Drugs In Clinical Trials.

December 22, 2006

In Brief: All 77 New NCI Positions Go to Carcinogenesis Programs; “Not Wisest Way To Use Them” – Newell

February 4, 1977

FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer

August 31, 2012